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Background: Gall bladder mucoceles (GBM) are a leading cause of biliary disease in dogs with
several breeds, including the Shetland Sheepdog, American Cocker Spaniel, Chihuahua, Pomera-
nian, and Miniature Schnauzer apparently predisposed.
Objective: To determine risk factors, clinical features, and response to treatment of GBM in
Border terriers (BT).
Animals: Medical records of 99 dogs (including 51 BT) with an ultrasonographic
(±histopathologic) diagnosis of GBM from three referral centers in the United Kingdom were
collected. A control group of 87 similar-aged BT with no ultrasonographic evidence of gall blad-
der disease was selected for comparison.
Method: Retrospective case-control study. Odds ratios were calculated to establish breed pre-
disposition. Signalment, presence of endocrine disease, clinicopathologic results, and outcome
were compared between the BT, other breeds, and control BTs.
Results: The odds of identifying a GBM in a BT in this hospital population was 85 times that of
all other breeds (95% confidence interval 56.9-126.8). BT had similar clinical signs and clinico-
pathologic changes to other breeds with GBM. There was no evidence that endocrinopathies
were associated with GBM in BT.
Clinical Significance: A robust breed predisposition to GBM is established for the BT.
KEYWORDS
biliary disease, hypercholesterolemia, cholecystectomy, liver, extrahepatic biliary tract
obstruction
1 | INTRODUCTION
Gall bladder mucoceles (GBM) are a leading cause of biliary disease in
the dog.1 A GBM is an accumulation of green-black, tenacious, and
immobile bile and mucus that provokes varying degrees of gall bladder
distension and biliary duct obstruction. Recent reports of GBM in
dogs reflect an increased awareness of the condition and greater
availability of abdominal ultrasound2 but also suggests that this might
be an emergent phenomenon.3
There is breed predisposition to GBM for the Shetland Sheep-
dog, American Cocker Spaniel, Chihuahua, Pomeranian, and Minia-
ture Schnauzer.2,4 The over-representation of particular purebred
dogs suggests a genetic contribution to GBM.5 An insertion mutation
in the ABCB4 gene was initially linked to GBM formation in Shetland
Sheepdogs6 but the association was not supported by a later study.7
Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST,
aspartate aminotransferase; BT, Border terrier; cBT, Border terrier belonging to
control group; GBM, gall bladder mucocele; GGT, gamma glutamyltranspepti-
dase; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglo-
bin concentration; MCV, mean corpuscular volume; non-BT, other non-border
terrier breeds; OR, odds ratio.
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The absence of a comparable condition in humans limits our under-
standing of the pathogenesis of GBMs in dogs. Recognized risk factors
for GBM formation include hyperadrenocorticism, hypothyroidism,8
hyperlipidemia,4 neonicotinoids,9 and recently, increased serum leptin.10
These conditions could act by altering the composition of bile and
mucin11 or through an effect on gall bladder motility.12 It is likely that
multiple mechanisms are involved in GBM development with both
genetic and epigenetic factors affecting each predisposed breed.13
It is our perception that over recent years an increasing number
of dogs presenting with GBM have been Border terriers (BT). The
number of registrations of BT puppies doubled between 2000 and
2004 and the breed is now established in the top 10 most popular
breeds in the United Kingdom. Epileptoid cramping syndrome14 and a
spongiform leukoencephalomyelopathy15 are in the breed but the BT
is not included among predisposed breeds for hypothyroidism,16
hyperadrenocorticism,17 diabetes mellitus,18 or hyperlipidemia.19
The primary objective of this multicenter, retrospective study was
to establish whether there is a breed predisposition for GBM in BT. A
second objective was to identify potential breed-specific characteris-
tics relating to risk factors, clinical features, and outcome for the BT
by comparing this group to non-BT breeds with GBM. Finally, the inci-
dence of endocrine disease and clinicopathologic abnormalities in BTs
was compared directly to a cohort of BTs unaffected by GBM in order
to explore potential GBM triggers in the breed.
2 | MATERIALS AND METHODS
Ethical approval was obtained from the institutional scientific and eth-
ical review committees for each of the participating centers.
Retrospective evaluation of medical records was performed to
identify all dogs with an ultrasonographic diagnosis of GBM present-
ing to Center 1 between January 2010 and September 2017, Center
2 between January 2014 and September 2017 and Center 3 between
January 2011 and September 2017. Enrollment criteria included an
ultrasonographic diagnosis of GBM determined by specialists in diag-
nostic imaging according to described criteria (briefly: hypoechoic/
anechoic gall bladder rim and echoic, immobile core of biliary sludge
with striated/stellate bands radiating out toward the periphery).20
Control Border terriers (cBTs) of similar ages to the BTs were
sought from each center and were included in the study if they had a
complete abdominal ultrasonographic examination with no evidence
of GBM. BTs with a description of an early or developing GBM were
excluded from the GBM and control groups.
For all GBM cases and cBTs, information recorded, where avail-
able, was: breed, age, sex, and neuter status, bodyweight; presence or
absence of previously diagnosed endocrinopathies (hyperadrenocorti-
cism, hypothyroidism, or diabetes mellitus), results of routine clinico-
pathologic testing (hematologic and serum biochemical profiles), and
total thyroxine measurement.
For GBM cases additional data was also collected from the medical
records including the presence or absence of specific clinical signs
(vomiting, diarrhea, abdominal pain, inappetence, lethargy, hypersaliva-
tion, weight loss, and icterus), approach to case management (surgical or
medical), medications prescribed, presence or absence of gall bladder
rupture (as recorded in the ultrasound, surgery or histopathology
reports), outcome (measured as number surviving beyond 7 days,
6 months and 1 year post surgery/diagnosis and total survival time), and
cause of death (classified as related to GBM or unrelated).
Clinicopathologic results were only included if they had been per-
formed within 72 hours of diagnosis of GBM (or in the case of cBTs,
the ultrasound examination) and if the tests had been performed on
an automated analyzer at a standard reference laboratory or using
automated systems and reagents at one of the study centers. Hema-
tologic variables included hematocrit, total RBC count, mean corpus-
cular volume, mean corpuscular hemoglobin, mean corpuscular
hemoglobin concentration, and total and differential leucocyte and
platelet counts. Serum biochemical tests included concentrations of
total protein, albumin, globulin, urea, creatinine, sodium, potassium,
chloride, calcium, phosphate, glucose, cholesterol, triglyceride, and
total bilirubin as well as activities of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), alkaline phosphatase (ALP), and
gamma glutamyltranspeptidase (GGT) activities.
Histopathology reports were reviewed and classified according to
World Small Animal Veterinary Association (WSAVA) guidelines;21 the
presence/absence of neutrophilic cholangitis (defined as a neutro-
philic infiltration predominantly involving portal regions of the liver),
cholangiohepatitis (extension of neutrophilic infiltration into the adja-
cent periportal region),22 and cholecystitis (neutrophilic infiltration of
the gall bladder wall)21 was noted. Culture results for bile, liver, and
gall bladder wall were also retrieved if available.
Referring veterinarians were contacted to provide follow-up
information including up-to-date clinical records and, if relevant, date
and cause of death. Owners were contacted to verify the dog's vital
status if the dog had not been seen by the referring vet within the
previous month.
For purposes of comparison, dogs were grouped as either BT or
non-BT. Dogs were also categorized according to whether they
underwent cholecystectomy or were managed medically. Dogs that
were euthanized without specific treatment for GBM were excluded
from this latter comparison.
2.1 | Calculations
Cohort selection for breed predisposition calculations was performed
according to the method outlined by Aguirre and others.2 Briefly, the
number of dogs seen by a referral clinician (excluding dogs under
2 years of age) with and without GBM and the number of each spe-
cific breed (eg, Border terrier) with and without GBM during the time
interval of this retrospective study were calculated. Odds ratio
(OR) calculations including 95% confidence intervals and p values
were performed using an online odds ratio calculator1. Breeds in
which the 95% confidence interval did not overlap 1.0 were consid-
ered to be significantly predisposed to GBM (at the 5% significance
level).
1Medcalc® statistical software: https://www.medcalc.org/calc/odds_ratio.php
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2.2 | Statistical analysis
An online statistical analysis program was used for calculations2. His-
tograms and the Shapiro-Wilk test were used to evaluate data distri-
butions for normality. Categorical data and clinicopathologic variables
which had non-Gaussian distributions were analyzed by use of non-
parametric statistical analyses. Descriptive statistics for these vari-
ables were expressed as median values and total or interquartile
ranges. Categorical data were expressed as frequencies for each
group. The Mann-Whitney test was used to detect differences in
median age, bodyweight, and clinicopathologic variables between the
BTs and non-BTs and BTs and cBTs.
Fisher's exact test was performed to evaluate the differences
between groups (BTs versus non-BTs and BTs versus cBTs,) with
regards to sex and neuter status and individual endocrinopathy inci-
dence. Fisher's exact test was also used to compare frequency of pre-
sentation of specific clinical signs (vomiting, lethargy, inappetence,
abdominal pain, icterus, and diarrhea), gall bladder rupture status, fre-
quency of histopathologic abnormalities (neutrophilic cholangitis, cho-
langiohepatitis, and cholecystitis), and outcome at different time
intervals in BTs versus non BTs.
After censoring of euthanized animals, dogs diagnosed with GBM
were classified as medically managed or surgically managed (under-
went cholecystectomy). Clinical signs and outcome data for medically
managed and surgically managed dogs were compared using a Fisher's
exact test. A Mann-Whitney test was used to compare the number of
clinical signs between medically and surgically managed dogs.
A significance level of P ≤ .05 was modified with a Bonferroni
correction when comparing age, weight, and clinicopathologic vari-
ables such that P ≤ .0016 was considered significant. Statistical signif-
icance was set at a p value of ≤.0029 for the Fisher's exact test when
comparing frequency of clinical signs, histopathological abnormalities,
gall bladder rupture status, and outcome (after application of the Bon-
ferroni correction).
3 | RESULTS
A total of 64,640 dogs greater than 2 years of age were presented to
the three centers over the respective study periods. Of these,
848 (1.3%) were BTs. Ninety-nine dogs (51 BTs and 48 non-BTs
including 4 Affenpinschers, 3 Bichon Frises, 3 Cavalier King Charles
Spaniels, 3 Jack Russell Terriers, 3 Labrador Retrievers, 6 Miniature
Schnauzers, 3 Pomeranians, 5 Shetland Sheepdogs, 2 Shih-Tzus,
5 cross-breed dogs, and 11 other individual breeds) were diagnosed
TABLE 1 Number of gall bladder mucocele (GBM) cases per breed and total number of each breed presenting to each center (and combined
totals) over the study period
Breed
GBM cases/
dogs in breed
(Center 1)
GBM cases/
dogs in breed
(Center 2)
GBM cases/
dogs in breed
(Center 3)
Total
GBM/total
in breed
Odds ratio
(all centers)
All center 95%
confidence
limits
Affenpinscher 2/6 0/4 2/10 4/20 169.8 55.7–517.3
Bichon Frise 1/161 1/74 1/197 3/432 4.7 1.5–14.8
BT 15/208 18/232 18/408 51/848 85.0 56.9–126.8
Cavalier King Charles Spaniel 2/532 1/434 0/1015 3/1981 1.0 0.3-3.1
Chihuahua 1/168 0/162 0/277 1/607 1.1 0.2-7.7
Cocker Spaniel 0/800 1/676 0/1568 1/3044 0.2 0.0-1.5
Cockapoo 0/35 0/3 1/142 1/180 3.7 0.5-26.5
English Bull Terrier 1/77 0/31 0/103 1/211 3.1 0.4–22.5
English Setter 0/22 0/29 1/41 1/92 7.2 0.1-5.2
Golden Retriever 0/447 0/249 1/791 1/1487 0.4 0.1–3.1
Jack Russell Terrier 3/712 0/413 0/956 2/2081 0.9 0.3-3.0
Labrador Retriever 0/269 1/1121 2/3427 3/4817 0.4 0.1-1.2
Miniature Schnauzer 3/157 1/239 2/382 6/778 5.3 2.3–12.2
Pekingese 0/19 0/19 1/61 1/99 6.7 0.9-48.6
Pomeranian 1/46 0/44 2/65 3/155 13.2 4.2–42.2
Shetland Sheepdog 2/52 1/15 2/66 5/133 26.8 10.7–66.9
Shih Tzu 1/251 0/302 1/565 2/1118 1.2 0.3-4.8
Springer Spaniel 0/615 1/491 0/1286 1/2392 0.3 0.0-1.9
Toy Poodle 0/36 0/15 1/80 1/131 5.1 0.7-36.5
Weimeraner 0/118 0/63 1/211 1/392 1.7 0.2-12.0
Yorkshire Terrier 1/285 0/136 0/410 1/831 0.8 0.1-5.6
X-breed 0/965 4/1275 1/3564 5/5804 0.5 0.2
Odds ratio are presented for each breed with 95% confidence limits. Breeds displayed in bold typeface have 95% confidence intervals that do not
cross 1.0 and are considered predisposed breeds.
2GNU Project (2015). GNU PSPP for GNU/Linux (Version 0.8.5). Boston, MA:
Free Software Foundation. Available from: https://www.gnu.org/software/
pspp/documentation.html
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with a GBM based on ultrasound alone (34) or ultrasound with histo-
pathologic confirmation (65).
The proportion of dogs presenting with a GBM for each breed to
each center are shown in Table 1.
Of the 51 BTs with GBM, there were 4 (8%) intact males,
18 (35%) neutered males, 6 (12%) intact females, and 23 (45%) neu-
tered females. The BTs had a median age of 9 years 11 months (range
4 years 11 months to 13 years 11 months), and a median bodyweight
of 10.0 kg (range 4.9–13.6). The 48 non-BTs with GBM included
9 (19%) intact males, 22 (46%) neutered males, 3 (6%) intact females,
and 14 (29%) neutered females. They had a median age of 9 years
1 month (range 2 years 8 months to 15 years 0 month) and median
bodyweight of 9.7 kg (range 2.7–37.9). There were no significant dif-
ferences in age (P = .24), bodyweight (P = .77), sex (P = .044), or neuter
status (P = .63) between BTs and non-BTs.
Eighty-seven cBTs that met the inclusion criteria were identified.
The median age of the cBTs was 8 years 8 months (range 1 years
7 months to 15 years 11 months) which was younger than the BT
group (P = .037). cBTs were diagnosed with a wide range of different
conditions that were broadly grouped into the following categories:
gastrointestinal (n = 29), neurological (16), hepatic/pancreatic (11),
oncological (7), renal (7), endocrine (6), cardiorespiratory (4), hemato-
logic (2), orthopedic (2), ophthalmic (1), reproductive (1), or dermato-
logic (1) disease.
The most frequent clinical signs at initial presentation in all
99 dogs with GBM were vomiting (80%), lethargy (70%), inappetence
(69%), icterus (35%), abdominal pain (34%), and diarrhea (24%).
Table 2 shows a comparison of the frequency of the clinical signs in
BTs and non-BTs. No significant differences in clinical signs were
found between these groups.
A total of 24 dogs (4 BTs, 14 non-BTS, and 6 cBTs) were pre-
sented with a single previously confirmed endocrinopathy and 5 dogs
(1 BT, 3 non-BTS, and 1 cBT) had been previously diagnosed with two
endocrine conditions (Table 3). Incidence rates for individual endocri-
nopathies were not significantly different between either the BT and
non-BT groups or between BTs and cBTs (Table 3).
Leucocytosis was present in 40% (35/88) of dogs with GBM at
presentation as well as neutrophilia (48%; 41/86), lymphopenia (41%;
35/86), monocytosis (51%; 44/86), eosinopenia (35%; 30/86), and
thrombocytosis (29%; 25/86)/thrombocytopenia (3%; 3/86). The
most common serum biochemical abnormalities found in dogs with
GBM were increased ALP activity(97%; 90/93), hypercholesterolemia
(93%; 81/87), increased ALT activity (91%; 82/90), GGT activity (85%;
61/72), AST activity (82%; 36/44), hyperbilirubinemia (72%; 65/90),
hypertriglyceridemia (66%; 25/38), and hypokalemia (20%; 14/70).
About 56% of dogs (10/18) with GBM tested, had low serum total thy-
roxine (T4).
Median total bilirubin was significantly greater in BTs than non-
BTs (P = .001) and the proportion of hyperbilirubinemic BTs (42/48,
88%) was greater than the non-BTs (23/42, 55%). Median cholesterol
was not significantly different between BTs and non-BTs (P = .66).
Median values (and interquartile ranges) for the hematologic and bio-
chemical variables of BTs, non-BTs and cBTs are shown in Tables 4
and 5. P values for Mann Whitney comparisons between BTs and
non-BTs and BTs and cBTs are also shown. The incidence of values
outside the reference range are also included.
About 65/77 dogs with GBM that underwent cholecystectomy
had gall bladder histopathology and 54/65 had liver histopathology.
Neutrophilic cholangitis was present in 23/28 BTs and 14/26 non-
BTs (P = .040), cholangiohepatitis in 13/28 BTs and 17/26 non-BTs (P
= .18) and cholecystitis in 11/37 BTs and 9/28 non-BTs (P = 1.0).
Culture results were available for bile (46 dogs), gall bladder wall
(18 dogs), and liver (13 dogs). Among the BTs 1/25 had a positive bile
culture (Enterococcus faecalis) and the same dog had a positive culture
of gall bladder wall (1/12); all 7 liver cultures were negative. Concern-
ing the non-BTs, 3/21 had a positive bile culture (2 Escherichia coli and
TABLE 2 Frequency of clinical signs in dogs with gall bladder mucoceles separated to allow comparison according to breed [BTs vs other breeds
(non-BTs)] and management approach (medical vs surgical)
Clinical signs
BT
(n = 51)
Non-BT
(n = 48) P value
Medical management
(n = 12)
Surgical management
(n = 77) P value
Vomiting 44 (86%) 35 (73%) .13 5 (42%) 67 (87%) .001
Diarrhea 8 (16%) 16 (33%) .06 3 (25%) 19 (25%) 1.0
Abdominal pain 20 (39%) 14 (29%) .40 1 (8%) 28 (36%) .094
Inappetance 38 (75%) 30 (63%) .28 5 (42%) 55 (71%) .052
Lethargy 38 (75%) 31 (65%) .38 6 (50%) 57 (74%) .10
Hypersalivation 2 (4%) 1 (2%) 1.0 0 (0%) 2 (3%) 1.0
Weight loss 5 (10%) 4 (8%) 1.0 0 (0%) 8 (10%) .59
Icterus 20 (39%) 15 (31%) .53 0 (0%) 31 (40%) .0067
Values in bold typeface were significantly different (Bonferroni corrected P value ≤ .0029).
Ten dogs that were not treated specifically for their GBM were censored from the comparison of medically and surgically-managed dogs.
TABLE 3 Number of previously diagnosed endocrinopathies in BTs,
other breeds (non-BTs), and cBTs
Dogs with GBM
Dogs
without GBMCases of
endocrine
disease
BTs
(n = 51)
Non BTs
(n = 48)
cBTs
(n = 87)
Diabetes mellitus 2 (3.9%) 4 (8.3%) 3 (3.5%)
Hyperadrenocorticism 3 (5.9%) 8 (16.7%) 3 (3.5%)
Hypothyroidism 1 (2.0%) 5 (10.4%) 1 (1.2%)
About 5 dogs (1 BT, 3 non-BTS and 1 cBT) were diagnosed with two
endocrine conditions. 2 dogs (1 BT and 1 non-BT) had hypothyroidism
and diabetes mellitus, 2 non-BT had hypothyroidism and hyperadre-
nocorticism and 1 cBT was diagnosed with hyperadrenocorticism and
diabetes mellitus.
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1 Enterobacteriacae sp.) and 1/6 non-BTs had a positive culture of gall
bladder wall (E. coli); 1/6 liver cultures was positive (Clostridium sp.).
Of the 99 dogs with GBM, 8 dogs [3 BTs (6%) and 5 non-BTs
(10%)] were euthanized within 3 days of obtaining an ultrasono-
graphic confirmation of GBM and without further treatment. Two
non-BTs, a Shih-Tzu with concurrent gastric neoplasia and a Weimer-
aner with a diagnosis of mediastinal squamous cell carcinoma were
discharged without treatment for their GBM and euthanized after
27 and 54 days, respectively, for reasons unrelated to the GBM.
Seventy-seven dogs [43 BTs (84%) and 34 non-BTs (71%)] underwent
cholecystectomy and 12 dogs [5 BTs (10%) and 7 non-BTs (15%)]
were managed medically. Gall bladder rupture was identified in 18/51
(35%) of BTs and 14/48 (29%) of non-BTs and was not significantly
different (P = .53) between BTs and non-BTs. Of the 77 surgically
managed dogs, 9 dogs (7 BTs and 2 non-BTs) died in the first week
after cholecystectomy (7-day surgical case fatality rate of 11.7%).
Three (2 BTs, 1 non-BT) of the 9 dogs that died within 7 days of cho-
lecystectomy had gall bladder rupture identified at surgery. Overall
3/30 dogs with gall bladder rupture died within 7 days which was not
significantly different from the 6/59 dogs without gall bladder rupture
that died in the same period (P = 1.0) (Table 6).
Of the 12 dogs with an ultrasonographic diagnosis of GBM man-
aged medically, concurrent endocrinopathies were seen in 4/12 dogs
(3 dogs with hyperadrenocorticism and 1 with diabetes mellitus).
Ursodeoxycholic acid and s-Adenosylmethionine (1), trilostane (3),
insulin (1), or omeprazole (1) were used in 9/12 dogs.
Dogs that underwent cholecystectomy presented a median of
4/6 (range 0/6 to 6/6) clinical signs which was significantly (P < .001)
more than the medically managed dogs (median 1/6, range 0/6 to
4/6). Table 2 shows a comparison of the frequency of the clinical signs
in medically and surgically managed GBMs and the p values for the
Fisher's Exact comparison. Dogs managed by cholecystectomy were
significantly more likely to have presented for vomiting at or prior to
presentation (P < .001).
About 9/10 (90%) medically managed and 39/49 (80%) surgically
managed GBM cases survived greater than 1 year (Table 7); two addi-
tional dogs were alive at the end of the study period but the one-year
survival criteria had not yet been reached. There were no significant
differences in the proportions of dogs surviving to 7 days, 6 months,
or 1 year according to breed status or management approach
(Table 7). Median survival times could not be calculated for any of the
groups (<50% case fatality rate).
4 | DISCUSSION
In this study 99 cases of GBM were identified across three centers.
More than half of these cases were BTs with similar proportions at
each site indicating that this is not an issue pertaining to a single loca-
tion, although might be unique to the United Kingdom. The strongly
suspected BT breed predisposition was validated by an OR of
85 (95% confidence interval 56.9–126.8). Odds ratios, by nature of
their calculation, tend to overestimate relative risk but, given the low
incidence of GBM in all breeds in this study population (compatible
with the rare disease assumption), any difference should be minimal.23
BT have not been previously identified as being predisposed to
GBM. The authors are aware of only three BTs with GBM included in
previous studies.9,24 This could, however, be an underestimate given
that a complete breakdown of breeds was not always reported. The
recent recognition of GBM within this breed might partly reflect the
increasing size of the UK's BT population. The Kennel Club 2015
report highlighted that the most popular 10% of BT sires were respon-
sible for 1 in every 3 BT puppies born since 2001 raising concerns as
to potential loss of genetic diversity within the breed. Pedigree analy-
sis was not performed in our study but, on this basis, merits further
investigation.
Our study also offers further supportive evidence for important
breed predilection among Shetland Sheepdogs, Pomeranians, and
Miniature Schnauzers as previously described.2,4 Cocker spaniels
(English and American) were underrepresented (OR < 1) in contrast to
American Cocker Spaniels in Japan that had an OR of 8.94.4 Cocker
Spaniel populations from different continents might represent differ-
ent genotypes with divergent predisposition to GBM. Indeed, Ameri-
can Cocker Spaniels in Japan present a phenotypically different form
of chronic hepatitis to that reported in Europe and The United
States.25
The OR for GBM diagnosis in Affenpinschers [179.8
(55.7–517.3)] was even higher than that for BTs although the total
cohort size was small (20) meaning that the findings should be inter-
preted with caution due to risk of a type I error. Identification of a
disease-susceptible population can help guide the search for contrib-
uting genes via genome-wide association studies (GWAS) especially if
multiple affected breeds can be used.26 This study highlights several
candidate breeds for such investigations.
In our study, pre-existing hyperadrenocorticism, hypothyroidism,
and diabetes mellitus were reported in 5.9%, 2%, and 3.9% of BTs and
17%, 10.4%, and 8.3% of non-BTs, respectively. Previous studies have
reported incidence rates of hyperadrenocorticism in 13% and 21%
dogs with GBM, hypothyroidism in 13% and 14%, and diabetes melli-
tus in 11.7% and 2%.2,8,9,24,27 Both hypothyroidism, and hyperadreno-
corticism have been shown to be significant risk factors for GBM
formation8,9 and also for gall bladder sludge accumulation.28 A previ-
ous study found that the incidence of diabetes mellitus in GBM cases
was not different from the matched control group8 refuting a role of
diabetes mellitus in GBM formation. No differences in the frequencies
of individual endocrinopathies was found between BTs and cBTs in
our study suggesting that these conditions might not be associated
with GBM formation in this breed.
Interestingly, in another study, 56% of cases of hyperadrenocorti-
cism and 45% of hypothyroidism cases were suspected at initial pre-
sentation but only confirmed in the 6 months after GBM diagnosis.8
Due to a lack of detailed follow-up, endocrinopathies diagnosed after
GBM diagnosis were not included in our study and any role of endo-
crine disease in our study might be underestimated.
There were statistically significant differences in the median
values of the white blood cells for BTs compared with the cBTs. The
median leucocyte, neutrophil, and monocyte counts were greater in
BTs while median eosinophil and lymphocyte numbers were lower
compared with the cBTs. This combination of differences could repre-
sent an exaggeration of the non-specific stress leucogram expected in
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ill animals due to acute endogenous corticosteroid production.2 An
increased neutrophil count may also reflect the inflammatory
response to concurrent cholangitis, cholecystitis, or bile peritonitis.2,29
Unfortunately, cytological review of a blood smear was inconsistently
performed and, thus morphological features of the neutrophils (toxic
change, presence of a left shift) were not included in this study.
A higher leucocyte count in dogs with GBM was found in non-
survivors compared with survivors in two previous studies.2,30 How-
ever, these findings have not been replicated in other studies23 and
the prognostic value of leucocytosis remains uncertain. While the
median neutrophil count of the BTs was significantly higher than the
non-BTs in this study there was a greater proportion of non-BTs with
neutrophilia. This contradiction limits interpretation of the significance
of the higher median neutrophil count in the BTs. Neutrophilic leuco-
cytosis has been associated with bile peritonitis2 although the inci-
dence of gall bladder rupture was also not different between the
groups in our study.
Biochemical findings in both the BTs and non-BTs were similar to
those described for dogs with GBM.1,2,24,27,31 Increased liver serum
enzyme activities, particularly ALP and GGT, were seen in greater than
85% cases and this combination of findings is considered highly spe-
cific (94%) for hepatobiliary disease.32 Hyperbilirubinemia was
recorded in 65/90 GBM cases but was only manifested as visible
icterus in 35/99 cases reflecting the higher optical threshold for clini-
cal icterus.33 BTs had higher median total bilirubin and were more
likely to be hyperbilirubinaemic than non-BTs, potentially reflecting an
increased incidence of biliary obstruction/cholestasis, pancreatitis,
sepsis, or bacterial cholangitis in this cohort.29 Cannulation of the
common bile duct is commonly performed during cholecystectomy.24
It was not possible to ascertain the degree of difficulty of bile duct
catheterization from the surgical records in our study or whether this
procedure was more frequently performed in the BTs. Future studies
could look to evaluate breed particularities associated with biliary
obstruction and the therapeutic advantage of biliary decompression.
Hyperlipidemia was identified in 84/87 GBM cases (3 non-BTs
had hypertriglyceridemia without hypercholesterolemia). Median
cholesterol and triglyceride values were higher in BTs than cBTs
although cBTs may have been more likely to be appropriately fasted
prior to blood sampling. Post-prandial hyperlipidemia is considered
unlikely to have played a significant role, as the majority of GBM dogs
were inappetent at presentation. Our statistical analysis compared
median values for the different groups of dogs; this approach might
overlook significant differences in the proportions of dogs with
hypercholesterolemia.
Marked hypercholesterolemia in the context of GBM is sugges-
tive of bile duct obstruction1 although other conditions, including
endocrinopathies (hyperadrenocorticism, hypothyroidism, and diabe-
tes mellitus), protein losing nephropathy, pancreatitis, or obesity may
also have contributed to this biochemical abnormality in the dogs
included in this study. Given that excretion in the bile is the principal
pathway for cholesterol elimination from the body,34 any impairment
of gall bladder motility, as thought to occur with GBM12 could be
expected to cause hypercholesterolemia. Hypercholesterolemia could
also have a contributory role in GBM formation. Supersaturation of
bile with cholesterol has been associated with impaired gallbladder
motility in people35 and sludge formation in dogs4 and thus, may be a
precursor to GBM formation. However, gall bladder sludge, while
prevalent in older dogs, has not been shown to progress toward sig-
nificant biliary disease over the course of a year36 and might not rep-
resent a risk factor in its own right. A recent study into the
mechanisms of GBM formation identified a disproportionate increase
in the gel-forming mucin Muc5ac relative to Muc5b, defective mucin
un-packaging and altered levels of mucin-interacting proteins as
potential contributory factors.3 The role of cholesterol in these pro-
cesses remains uncertain although the expression of certain mucin
genes has been linked to cholesterol-associated gallbladder disease in
people.37
The higher prevalence of primary hypercholesterolemia in the
Shetland Sheepdog38 and hypertriglyceridemia with or without hyper-
cholesterolemia in the Miniature Schnauzer34 may, at least partially
account for these breeds’ predisposition to GBM. However, not all
Shetland Sheepdogs with GBM manifest hyperlipidemia2 and choles-
terol concentrations were not significantly different in GBM cases com-
pared with control dogs.4 Our study did not establish an association of
hypercholesterolemia with GBM in BTs. However, the precise role of
cholesterol as contributor to, or consequence of GBM formation merits
further interrogation. Further longitudinal studies are necessary to con-
firm the importance of hypercholesterolemia as a risk factor for GBM.
Potassium concentrations were significantly lower in the BTs com-
pared with non-BTs and cBTs. This electrolyte has previously been sug-
gested to have prognostic importance in GBM cases as non-survivors
had lower potassium compared with survivors.2 The lower total thyrox-
ine (T4) levels in BTs compared with cBTs could reflect a greater inci-
dence of undiagnosed hypothyroidism as cTSH measurements (or wider
thyroid panels) were not routinely performed. An alternative explanation
would be non-thyroidal illness secondary to the complications of hepa-
tobiliary disease. Undiagnosed hypothyroidism could also have contrib-
uted to the high prevalence of hypercholesterolemia among BTs,
although, this may also be associated with cholestasis in the context of
the GBM. Future prospective studies serially interrogating the thyroid
axis should clarify this important point more fully. Follow-up data estab-
lishing thyroid status was unfortunately not available to permit clarifica-
tion in the current cohort.
Cholecystitis occurs in 5%-33% of dogs with GBM24,27,31 and in
80% of Shetland Sheepdogs.2 The identification of cholecystitis in
11/37 (30%) BTs in this study does not support a primary role for gall
bladder inflammation in GBM formation in this breed. Cholangitis was
TABLE 6 Seven-day survival data for dogs with gall bladder
mucoceles according to gall bladder rupture status separated
to allow comparison according to breed [BTs vs other breeds
(non-BTs)]
Proportion of animals
that died within 7 days
Dogs
with
GBM
With gall
bladder
rupture
Without
rupture
P
value
BTs 2/17 5/31 P = 1.0
Non BTs 1/13 1/28 P = .54
All dogs 3/30 6/59 P = 1.0
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found in 23/28 (82%) BTs in this study compared with 30%-45% of
dogs with GBM in previous studies.2,24 Gallbladder disease has been
implicated as a primary cause of intrahepatic cholangitis in dogs
and can occur with GBM without concurrent cholecystitis.39 The 10%
(6/63) incidence of positive culture of gallbladder contents (bile or
gall bladder wall) is within the 3%-70% range of previous
reports2,24,27,30,31,40 and might have been underestimated by pre-
operative antibiotic therapy24,27,40 (not investigated in this study).
Pathogens identified in the gallbladder contents and liver in this study
have been reported.1,29,39,40
Dogs lacking clinical signs referable to hepatobiliary disease and
in which the GBM was an incidental finding have previously been
reported.2,27,41 In our study 12 dogs were managed medically. These
dogs presented fewer clinical signs and a lower incidence of vomiting
than dogs that underwent cholecystectomy. Our study demonstrates
that appropriately selected cases can be managed without surgery as
9/10 cases have survived for more than 1 year. However, outcome
comparison is subject to an inherent bias through targeted selection
of less clinically affected animals for medical therapy. Two previously
reported cases had complete resolution of GBM within 4 months
without surgical intervention.42 Follow-up ultrasound reports were
rarely available for the medically managed cases in our study prohibit-
ing an objective evaluation of treatment efficacy beyond survival
status.
The 11.7% case fatality rate at 7 days is similar to other reports;
case fatality rates for GBM dogs undergoing cholecystectomy have
been between 7% and 32%.2,24,27,31,43 Gall bladder rupture was not
shown to have a negative effect on survival although this could
reflect a type II error due to the low numbers of dogs with rupture in
this study. A recent larger study found that dogs with rupture of the
gall bladder were 2.7 times more likely to die than dogs without rup-
ture.40 In this study, dogs that underwent cholecystectomy and sur-
vived the initial perioperative period had an extended survival time
(MST still not reached), in agreement with previous studies.27
Our study did have limitations. The multicenter approach meant
that blood work was performed at more than one laboratory with
slightly different reference ranges. Data has been presented as
absolute values, rather than percentages above/below the reference
range to facilitate interpretation. Endocrine disease testing prior to,
or, at presentation was often incomplete leading to potential under-
estimation of the incidence of these disorders. Furthermore, there
was an absence of consistent long-term follow up meaning that
endocrinopathies subsequently diagnosed could not be included in
the analysis. Ultrasonographic changes affecting the gall bladder
consistent with early or developing GBMs were also excluded
potentially leading to an underestimation of GBM cases. Peculiari-
ties in the non-BT group could have skewed any comparison with
the BT group given the possibility of an increased incidence of par-
ticular metabolic or endocrinopathic conditions therein (eg, hyper-
lipidemia in Miniature Schnauzers). This could have led to false
association (or lack thereof ) between underlying diseases or bio-
chemical abnormalities. A larger non-BT group would be required to
help interrogate this further. A clear limitation of the cBT group is
that they were not a healthy cohort. Therefore, despite the lack of
ultrasonographic evidence for GBM, any comparison between
groups in relation to clinical signs or blood-work abnormalities must
be interpreted with caution. The BT and cBT groups were not age-
matched; the cBT group were younger. This therefore raises the
question as to whether some of these cBT would have developed
GBM should they have been presented at an older age. As with the
previous point, this limits the ability to identify risk factors.
In conclusion, our study provides robust evidence for a predispo-
sition to GBM in the BT breed. The Affenpinscher is also potentially
predisposed and merits evaluation of a greater number of cases. Simi-
lar to findings from previous studies in non-BT breeds, the etiology of
GBM formation in BTs, is likely to be multi-factorial, reflecting the
presence of one or more risk factors in a predisposed individual. Fur-
ther studies of BTs are warranted to identify factors influencing this
predisposition. The BT represents a suitable candidate breed for
future genetic association studies.
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TABLE 7 Outcome data for dogs with gall bladder mucoceles separated to allow comparison according to breed [BTs vs other breeds
(non-BTs)] and management approach (medical versus surgical)
BTs Non-BTs P value Medically managed dogs Surgically managed dogs P value
7 day survival 41/48 (85%) 39/41 (95%) .17 12/12 (100%) 68/77 (88%) .60
6 month survival 33/41 (80%) 31/35 (89%) .37 10/11 (91%) 54/65 (83%) .68
1 year survival 26/34 (76%) 22/25 (88%) .33 9/10 (90%) 39/49 (80%) .67
About 3 BTs and 7 non-BTs were euthanized without treatment and are excluded from survival analysis.
About 13 dogs were still alive at time of writing but had survival times less than 6m.
About 29 dogs were still alive at time of writing but had survival times greater than 6 m but less than 1 year (includes the 13 dogs above).
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